Publications

Found 32 results
Filters: Evidence-cd32a-does-not%C2%A0mark-hiv-1-latent-reservoir is   [Clear All Filters]
2017
Jones R.B..  2017.  Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.. Biomaterials. 117
Pollack R.A..  2017.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.. Cell Host Microbe. 21(4)
Cruz CRussell, Bollard CM.  2017.  HIV Receives a "One Two Knockout Punch".. Mol Ther. 25(3):566-567.
Raposo R.A..  2017.  IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis.. JCI Insight. 2(1)
Lin X..  2017.  Inhibition of HIV-1 infection in humanized mice and metabolic stability of protein phosphatase-1-targeting small molecule 1E7-03. . Oncotarget. 8(44)
Mujib S..  2017.  Pharmacologic HIV-1 Nef blockade promotes CD8 T cell-mediated elimination of latently HIV-1-infected cells in vitro.. JCI Insight. 2(17)
Bardhi A, Wu Y, Chen W, Li W, Zhu Z, Zheng JHua, Wong H, Jeng E, Jones J, Ochsenbauer C et al..  2017.  Potent NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.. J Virol. 91(20)
Lin X..  2017.  Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals.. Curr Pharm Des. 23(28)
Thomas A.S.  2017.  T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.. PLoS Pathog. 13(9)
Flerin NC, Chen H, Glover TD.  2017.  TCR Clonotype-specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T Cell Clones is Not Mediated by TCR Alone. American Society for Microbiology Journals.
2018
Bronnimann MP, Skinner PJ, Connick E.  2018.  The B-Cell Follicle in HIV Infection: Barrier to a Cure.. Front Immunol. 9:20.
Clutton GTyndale, R Jones B.  2018.  Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure.. Front Immunol. 9:1452.
Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang S-H, Ren Y, Spivak AM, R Jones B, Planelles V et al..  2018.  Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.. JCI Insight. 3(19)
Strongin Z, Sharaf R, D VanBelzen J, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U et al..  2018.  Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.. J Virol. 92(12)
Osuna CE, Lim S-Y, Kublin JL, Apps R, Chen E, Mota TM, Huang S-H, Ren Y, Bachtel ND, Tsibris AM et al..  2018.  Evidence that CD32a does not mark the HIV-1 latent reservoir.. Nature. 561(7723):E20-E28.
Bachtel ND, Beckerle GA, Mota T, Rougvie Mde Mulder, Raposo RAndre, R Jones B, Nixon DF, Apps R.  2018.  Expression of host restriction factors by memory CD4+ T cells differs between healthy donors and HIV-1 infected individuals with effective ART.. AIDS Res Hum Retroviruses.
Bachtel ND, Umviligihozo G, Pickering S, Mota TM, Liang H, Del Prete GQ, Chatterjee P, Lee GQ, Thomas R, Brockman MA et al..  2018.  HLA-C downregulation by HIV-1 adapts to host HLA genotype.. PLoS Pathog. 14(9):e1007257.
Webb G.M..  2018.  The human IL-15 superagonist ALT-803 directs SIV-specific CD8(+) T cells into B-cell follicles.. Blood Adv.. 2(2)
Macedo A.B..  2018.  Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.. AIDS Res Hum Retroviruses. 34(9)
Huang S.H..  2018.  Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.. J Clin Invest. 128(2)
Pinzone MRita, O'Doherty U.  2018.  Measuring integrated HIV DNA ex vivo and in vitro provides insights about how reservoirs are formed and maintained.. Retrovirology. 15(1):22.
Jones B.R..  2018.  Phylogenetic approach to recover integration dates of latent HIV sequences within-host.. Proc Natl Acad Sci U S A. 115(38)